Objective: To explore the association of VEGFR2 gene polymorphisms (rs2305948 and rs1870377) with the effect of levodopa (L-dopa) and dyskinesia in Chinese population and to provide theoretical basis for clinical treatment.
Methods: By using Taqman MGB analysis and gene sequencing, the rs2305948 and rs1870377 polymorphisms of 69 enrolled Parkinson's disease (PD) patients were detected. Among them, 32 cases developed dyskinesia during 5 years and 37 cases did not develop dyskinesia during 8 years (as the control).
Results: There was no significant association between the occurrence of dyskinesia and VEGFR2 polymorphisms at rs2305948 and rs1870377. However, rs1870377 polymorphism of AA showed greater maximum L-dopa dose [(565.00±163.55) mg/d vs (396.88±200.39) mg/d, (300.00±80.18) mg/d, P=0.038] and higher value of Modified Abnormal Involuntary Movement Scale (mAIMS) compared with that with polymorphisms of AT and TT [17.00±5.24 vs 8.94±6.53, 7.86±4.45, P=0.026].
Conclusion: VEGFR2 genes polymorphism (rs1870377) is associated with maximum L-dopa dose and mAIMS value in PD patients.
目的：探讨中国人群中血管内皮生长因子受体2(vascular endothelial growth factor receptor 2，VEGFR2)基因rs2305948和rs1870377位点多态性分布与帕金森病(PD)患者使用左旋多巴的疗效和运动障碍的关系，为临床治疗提供理论依据。方法：收集69例PD患者，其中32例使用左旋多巴治疗5年内发生运动障碍，为实验组；37例使用左旋多巴治疗8年以上未发生运动障碍，为对照组。采用Taqman MGB探针方法和基因测序，对2组患者的VEGFR2基因rs2305948和rs1870377的多态性进行分析。结果：2组rs2305948和rs1870377位点不同基因多态性间差异无统计学意义(P>0.05)。rs1870377位点AA型的最大左旋多巴使用剂量显著高于AT型和TT型[(565.00±163.55) mg/d vs (396.88±200.39) mg/d，(300.00±80.18) mg/d，P=0.038]；且AA型的改良版运动障碍评定量表(Modified Abnormal Involuntary Movement Scale，mAIMS)分值显著高于AT型和TT型[(17.00±5.24) vs (8.94±6.53)，(7.86±4.45)，P=0.026]。结论：VEGFR2基因rs1870377基因多态性与最大左旋多巴使用剂量、mAIMS 量表值相关。.